ArticleHNO2025
[Benign parotid tumors : Surgery and management of perioperative complications].
Article in HNO, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumors of the parotid gland are rare and predominantly benign. The surgical management is challenging due to the close anatomical relationship to the facial nerve. Pleomorphic adenoma and cystadenolymphoma are among the most frequently occurring lesions. The surgical approach depends on the location, size and suspected diagnosis of the lesion. While radical surgical techniques were favored in the past, current practice emphasizes reducing surgical morbidity through less invasive resection methods. In this context, extracapsular dissection offers functional advantages over more extensive resections, with similarly low recurrence rates. Complications such as facial nerve palsy, salivary fistulas and Frey's syndrome occur less frequently with milder severity and are generally well-treatable, for example, with botulinum toxin. In selected cases, such as confirmed bilateral cystadenolymphoma, a conservative wait-and-scan approach may be considered as an alternative to surgery. The goal remains the complete resection of the lesion with maximum preservation of function.
Indexed as
Identifiers
41091150What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.